Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Accured Expenses: 2012-2025

Historic Change in Accured Expenses for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to -$19.0 million.

  • Ptc Therapeutics' Change in Accured Expenses fell 236.17% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.9 million, marking a year-over-year decrease of 2142.47%. This contributed to the annual value of -$33.3 million for FY2024, which is 168.92% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Change in Accured Expenses stood at -$19.0 million, which was up 46.90% from -$35.8 million recorded in Q2 2025.
  • Ptc Therapeutics' Change in Accured Expenses' 5-year high stood at $36.8 million during Q4 2021, with a 5-year trough of -$35.8 million in Q2 2025.
  • Its 3-year average for Change in Accured Expenses is -$1.9 million, with a median of $6.0 million in 2024.
  • As far as peak fluctuations go, Ptc Therapeutics' Change in Accured Expenses skyrocketed by 723.26% in 2021, and later tumbled by 2,171.02% in 2024.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Change in Accured Expenses stood at $36.8 million in 2021, then fell by 29.36% to $26.0 million in 2022, then tumbled by 69.54% to $7.9 million in 2023, then plummeted by 461.34% to -$28.6 million in 2024, then slumped by 236.17% to -$19.0 million in 2025.
  • Its last three reported values are -$19.0 million in Q3 2025, -$35.8 million for Q2 2025, and $18.5 million during Q1 2025.